논문 요약 | Canagliflozin(SGLT-2 억제제)가 당뇨 환자에서 신장병증의 위험을 감소시키는가? CREDENCE trial

논문 제목 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

PMID: 30990260. https://www.nejm.org/doi/full/10.1056/NEJMoa1811744 Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy | NEJM Original Article from The New England Journal of Medicine — Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy www.nejm.org Key question 알부민뇨(ACR(Albumin to Creatinine Ratio) ...